Login

Journal Image
Current Cancer Therapy Reviews
ISSN (Print): 1573-3947
ISSN (Online): 1875-6301
VOLUME: 10
ISSUE: 1
DOI: 10.2174/157339471001140815152055









Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer

img
Author(s): Paul Brittain, S. Gail Eckhardt and Christopher H. Lieu
Pages 34-38 (5)
Abstract:
The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.
Keywords:
Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.
Affiliation:
University of Colorado School of Medicine, Division of Medical Oncology, 12801 E. 17th Avenue, Mail Stop 8117, Research 1 South, Aurora, Colorado 80045-2530.